Search
Now showing items 1-6 of 6
Comparative effects of 18 antipsychotics on metabolic function in schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis
(2019-10)
Background: Antipsychotic-treatment is associated with metabolic disturbance. However, the relative degree to which metabolic alterations occur in treatment with different antipsychotics remains unclear. Furthermore, ...
How Efficacious Are Antipsychotic Drugs for Schizophrenia? An Interpretation Based on 13 Effect Size Indices
(2021-08)
Background
The magnitude of the superiority of antipsychotics over placebo is debated. One reason is that the effect-size index which is usually used in meta-analyses is in standard deviation units. Many other indices, ...
Representation and Outcomes of Individuals With Schizophrenia Seen in Everyday Practice Who Are Ineligible for Randomized Clinical Trials
(2022-02)
IMPORTANCE Most evidence about efficacy and safety of antipsychotics in schizophrenia
spectrum disorders relies on randomized clinical trials (RCTs). However, owing to their strict
eligibility criteria, RCTs represent ...
Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis
(2022-02)
Schizophrenia is a common, severe, and usually chronic disorder. Maintenance treatment with antipsychotic drugs can prevent relapse but also causes side-effects. We aimed to compare the efficacy and tolerability of ...
Efficacy and Effectiveness of Antipsychotics in Schizophrenia: Combining Evidence from Randomised Controlled Trials and Real-World.
(2023-10)
Background: There is debate about the generalisability of results from randomised clinical trials (RCTs) to ‘real-world’ (RW) settings. Studying outcomes of treatments for schizophrenia can shed light on this issue and ...
Trace amine-associated receptor 1 (TAAR1) agonists for psychosis: protocol for a living systematic review and meta-analysis of human and non-human studies.
(2023-08)
Background: There is an urgent need to develop more effective and safer antipsychotics beyond dopamine 2 receptor antagonists. An emerging and promising approach is TAAR1 agonism. Therefore, we will conduct a living ...